| Authors: |
Hyams C; Academic Respiratory Unit, University of Bristol, Bristol, UK catherine.hyams@bristol.ac.uk.; Bristol Vaccine Centre, University of Bristol, Bristol, UK., Begier E; Global Medical and Scientific Affairs, Pfizer Inc, New York City, New York, USA., Garcia Gonzalez M; Population Health Sciences, University of Bristol, Bristol, UK.; Academic Respiratory Unit, Southmead Hospital, Bristol, UK., Southern J; Vaccines Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK., Campling J; Vaccines Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK., Gray S; Global Medical and Scientific Affairs, Pfizer Inc, New York City, New York, USA., Oliver J; Bristol Vaccine Centre, University of Bristol, Bristol, UK.; Schools of Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, UK., Gessner BD; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA., Finn A; Bristol Vaccine Centre, University of Bristol, Bristol, UK.; Population Health Sciences, University of Bristol, Bristol, UK. |